文献速递细菌感染、耐药与抗菌药物结核与非结核分枝杆菌

溴代丙酮酸乙酯作为广谱抗菌药物的再利用研究

Repurposing ethyl bromopyruvate as a broad-spectrum antibacterial.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

本研究评估溴代丙酮酸乙酯对结核分枝杆菌和ESKAPE病原体的抑制能力,发现其具有浓度依赖性杀菌活性,可抑制GAPDH等多个靶点,与现有药物无负面相互作用,并在小鼠中性粒细胞减少模型中疗效与万古霉素相当但剂量更低。

要点

  • 溴代丙酮酸乙酯对耐药和敏感结核分枝杆菌及ESKAPE病原体均有广谱抗菌活性。
  • 该化合物抑制GAPDH等多靶点,降低ATP水平和铁摄取,具有浓度依赖性杀菌作用。
  • 在S. aureus中性粒细胞减少大腿感染模型中,1/25剂量疗效与万古霉素相当。

核心结论

  • 溴代丙酮酸乙酯具备作为潜在广谱抗菌药物所需的全部特性。

研究设计与样本

  • 采用生长抑制实验评估溴代丙酮酸乙酯对结核分枝杆菌和ESKAPE病原体的抑制作用,并测定选择性指数、时间杀菌动力学、协同作用、生物膜清除、胞内杀菌及小鼠中性粒细胞减少S. aureus感染模型体内效力。

主要发现

  • 溴代丙酮酸乙酯对药物敏感和耐药的结核分枝杆菌及ESKAPE病原体均表现出等效的广谱抗菌活性。
  • 该化合物具有浓度依赖性杀菌活性,在结核分枝杆菌中抑制GAPDH并降低ATP水平和转铁蛋白介导的铁摄取。
  • 除GAPDH外,还不同程度抑制丙酮酸激酶、异柠檬酸裂解酶和苹果酸合酶。
  • 溴代丙酮酸乙酯与任何药物无负面相互作用,在比万古霉素低64倍的浓度下显著减少生物膜。
  • 在S. aureus中性粒细胞减少大腿感染模型中,1/25剂量下减少大腿细菌计数的疗效与万古霉素相当。

关键数值与推荐

  • 溴代丙酮酸乙酯在比万古霉素低64倍的浓度下显著减少生物膜。
  • 在S. aureus中性粒细胞减少大腿感染模型中,1/25剂量下疗效与万古霉素相当。

临床怎么用

  • 溴代丙酮酸乙酯可作为广谱抗菌药物开发的候选化合物,尤其针对耐药结核分枝杆菌和ESKAPE病原体感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The emergence of drug-resistant bacteria is a major hurdle for effective treatment of infections caused by Mycobacterium tuberculosis and ESKAPE pathogens. In comparison with conventional drug discovery, drug repurposing offers an effective yet rapid approach to identifying novel antibiotics. METHODS: Ethyl bromopyruvate was evaluated for its ability to inhibit M. tuberculosis and ESKAPE pathogens using growth inhibition assays. The selectivity index of ethyl bromopyruvate was determined, followed by time-kill kinetics against M. tuberculosis and Staphylococcus aureus. We first tested its ability to synergize with approved drugs and then tested its ability to decimate bacterial biofilm. Intracellular killing of M. tuberculosis was determined and in vivo potential was determined in a neutropenic murine model of S. aureus infection. RESULTS: We identified ethyl bromopyruvate as an equipotent broad-spectrum antibacterial agent targeting drug-susceptible and -resistant M. tuberculosis and ESKAPE pathogens. Ethyl bromopyruvate exhibited concentration-dependent bactericidal activity. In M. tuberculosis, ethyl bromopyruvate inhibited GAPDH with a concomitant reduction in ATP levels and transferrin-mediated iron uptake. Apart from GAPDH, this compound inhibited pyruvate kinase, isocitrate lyase and malate synthase to varying extents. Ethyl bromopyruvate did not negatively interact with any drug and significantly reduced biofilm at a 64-fold lower concentration than vancomycin. When tested in an S. aureus neutropenic thigh infection model, ethyl bromopyruvate exhibited efficacy equal to that of vancomycin in reducing bacterial counts in thigh, and at 1/25th of the dosage. CONCLUSIONS: Ethyl bromopyruvate exhibits all the characteristics required to be positioned as a potential broad-spectrum antibacterial agent.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Kumar A, Boradia VM, Thakare R, et al. Repurposing ethyl bromopyruvate as a broad-spectrum antibacterial. J Antimicrob Chemother. 2019. PMID: 30689890. doi:10.1093/jac/dky555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。